Immunotech Biopharm (6978) disclosed that its indirect non-wholly owned subsidiary, Beijing Yongtai Biologics Co., Ltd. (“Yongtai Beijing”), has entered into an Entrustment Service Agreement with Tianjin Tasly Pharmaceutical Group Co., Ltd. (“Tasly,” 600535.SH). Yongtai Beijing will provide Tasly with thawing, washing, formulation, filling, testing, and related project management services for a cell therapy project.

According to the agreement dated 27 January 2026, Tasly is scheduled to pay Yongtai Beijing a total service fee of RMB9.75 million (tax inclusive). This amount is tied to the number of clinical batches (222 planned) and may be adjusted if the service period extends beyond 24 months or if additional batches are required. The service fee is payable in six stages linked to the project’s progress.

Immunotech Biopharm (6978) noted that Tasly is an associate of one of its substantial shareholders, rendering the transaction a continuing connected transaction under Chapter 14A of the Listing Rules. As the highest applicable percentage ratio is over 0.1% but below 5%, the arrangement is subject to reporting, annual review, and announcement requirements but does not require independent shareholders’ approval. The intended annual caps for revenue from this agreement are RMB4.5 million, RMB5.0 million, and RMB2.5 million for the financial years ending 31 December 2026, 2027, and 2028, respectively.

Immunotech Biopharm (6978) focuses on research, development, and commercialization of T cell immunotherapy, and Yongtai Beijing’s GMP-compliant facilities and quality management systems position it to undertake entrusted cell therapy processing. The arrangement aligns with Immunotech Biopharm (6978)’s strategy to leverage its manufacturing and quality expertise for stable service income while enhancing collaboration with a key pharmaceutical group in China.